OncoSec Medical Inc (ONCS)

1.06
NASDAQ : Health Care
Prev Close 0.98
Day Low/High 0.96 / 1.06
52 Wk Low/High 0.88 / 2.08
Avg Volume 264.80K
Exchange NASDAQ
Shares Outstanding 20.87M
Market Cap 20.45M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness At Enhancing Tumor Immunogenicity In Preclinical Tumor Models

Data Presented at Keystone Symposia Conference "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology"

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

OncoSec Granted FDA Fast Track Designation For ImmunoPulse® IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab

Provides Opportunities for Upcoming Phase 2b PISCES Clinical Trial and Future Clinical Development

OncoSec To Host KOL Event Focused On New ASCO-SITC Melanoma Data And Clinical Strategy On Tuesday, February 28 In New York City

Key Opinion Leaders in Melanoma and Company Representatives to Discuss Unmet Needs in Immunotherapy

OncoSec To Present At NobleCon13

OncoSec To Present At NobleCon13

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

- OncoSec is Executing on a Melanoma Registration-Directed Clinical Program with Immunopulse® IL-12 and Anti-PD-1 Therapy

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

Company to Host Investor and Analyst Day on November 17, 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

Company to Host Investor and Analyst Day on November 17, 2016